Spectral MD has developed technology that will enable clinicians to make faster decisions about burns and diabetic foot ulcers. It has the backing of the Biomedical Advanced Research and Development Authority (BARDA) in the US, and this should ensure a US market for the technology.
There was already cash in the bank and the money raised in the flotation will help to complete clinical trials for the application for diabetic foot ulcers. Spectral also wants cash to build up a US distribution network as well as a sales infrastructure in Europe.
The share price ended the day at 62p. More than 326,...
